Thus, using ABCA1 agonists allows ApoE4 lipidation and was shown to reduce ApoE4-mediated Aβ42 accumulation and tau hyperphosphorylation in hippocampal neurons, as well as rescue synaptic impairments and cognitive deficits in ApoE4-targeted replacement mice [87]. The gene discussed is MAPT; the disease is Cognitive impairment.